Changes are coming to our lives and world that may rival the industrial and internet revolutions. Jeremy Schwartz and Kara Marciscano discuss the BioRevolution already underway and identify the range of business sectors we believe are best positioned to benefit.
Once fears of the delta variant subside and the recovery continues, we believe that small caps may continue as important pieces of the economic recovery. Until then, Brian Manby explains why investors should be wary of prevailing large-cap valuations in their portfolios.
The history of cap weighting may surprise investors. Jeff Weniger explains why WisdomTree chooses to weight by fundamentals.
After a decade of growth outperformance, value has taken over. For investors seeking value-like valuations with an investment process that favors quality, Jeremy Schwartz makes the case to consider our quality dividend growth Fund (DGRW).
No matter your economic forecast for the near future, Brian Manby explains why we think the WisdomTree U.S. MidCap Fund (EZM) could be a part of it.
For those looking to access the unique value opportunity in India, we prefer a strategy emphasizing these sectors as well as positive earnings in order to potentially benefit from continued economic growth. We believe the WisdomTree India Earnings Fund (EPI) may be able to deliver both.
When it comes to growth investing, there are some key challenges that investors face. Jeremy Schwartz and Kara Marciscano explain how our just launched U.S. Growth & Momentum Fund (WGRO) seeks to solve for these challenges.
